Detailed Information

Cited 40 time in webofscience Cited 43 time in scopus
Metadata Downloads

Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial

Authors
Zhao, ChenKim, Sae WoongYang, Dae YulKim, Je JongPark, Nam CheolLee, Sung WonPaick, Jae SeungAhn, Tai YoungMoon, Ki HakChung, Woo SikMin, Kweon SikSuh, Jun-KyuHyun, Jae SeogPark, KwangsungPark, Jong Kwan
Issue Date
Dec-2012
Publisher
WILEY-BLACKWELL
Keywords
avanafil; phosphodiesterase type 5 (PDE5) inhibitor; erectile dysfunction (ED); clinical study
Citation
BJU INTERNATIONAL, v.110, no.11, pp 1801 - 1806
Pages
6
Indexed
SCI
SCIE
SCOPUS
Journal Title
BJU INTERNATIONAL
Volume
110
Number
11
Start Page
1801
End Page
1806
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/35004
DOI
10.1111/j.1464-410X.2012.11095.x
ISSN
1464-4096
1464-410X
Abstract
OBJECTIVE To evaluate the efficacy and safety of avanafil, a new potent selective phosphodiesterase type 5 (PDE5) inhibitor, in patients with erectile dysfunction (ED). PATIENTS AND METHODS The present study was a multicentre, randomized, double-blind, placebo-controlled, fix-dosed phase three clinical trial involving 200 patients with ED. The subjects were treated with placebo or avanafil (100 or 200 mg) for 12 weeks and were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Questionnaire (GAQ). The primary outcome variable was the change from baseline for IIEF erectile function domain (EFD) score. The secondary outcome variables were SEP Q2 and Q3, the shift to normal rate (EFD = 26), and response to the GAQ. RESULTS Compared with placebo, patients who took 100 or 200 mg of avanafil had significantly improved IIEF-EFD score. There were similar results when comparing Q2 and Q3 in the SEP diary and the GAQ. Flushing was the most common treatment-related adverse event. Most adverse events were transient and mild or moderate in severity. CONCLUSION Avanafil is an effective and well-tolerated therapy for ED of broad-spectrum aetiology and severity.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Urology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Je Jong photo

Kim, Je Jong
Anam Hospital (Department of Urology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE